| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ... The Lancet 393 (10183), 1819-1830, 2019 | 453 | 2019 |
| Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance A Zippelius, P Batard, V Rubio-Godoy, G Bioley, D Liénard, F Lejeune, ... Cancer research 64 (8), 2865-2873, 2004 | 391 | 2004 |
| Four functionally distinct populations of human effector-memory CD8+ T lymphocytes P Romero, A Zippelius, I Kurth, MJ Pittet, C Touvrey, EM Iancu, P Corthesy, ... The Journal of Immunology 178 (7), 4112-4119, 2007 | 380 | 2007 |
| Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with rapamycin L Strauss, TL Whiteside, A Knights, C Bergmann, A Knuth, A Zippelius The Journal of Immunology 178 (1), 320-329, 2007 | 360 | 2007 |
| Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. A Zippelius, P Kufer, G Honold, MW Köllermann, R Oberneder, ... Journal of Clinical Oncology 15 (7), 2701-2708, 1997 | 347 | 1997 |
| Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for … E Putz, K Witter, S Offner, P Stosiek, A Zippelius, J Johnson, R Zahn, ... Cancer research 59 (1), 241-248, 1999 | 235 | 1999 |
| Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions N Rufer, A Zippelius, P Batard, MJ Pittet, I Kurth, P Corthesy, JC Cerottini, ... Blood 102 (5), 1779-1787, 2003 | 197 | 2003 |
| Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. heinz laeubli, A Zippelius | 192* | |
| Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma P Romero, D Valmori, MJ Pittet, A Zippelius, D Rimoldi, F Lévy, V Dutoit, ... Immunological reviews 188 (1), 81-96, 2002 | 184 | 2002 |
| Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial M Pless, R Stupp, HB Ris, RA Stahel, W Weder, S Thierstein, MA Gerard, ... The Lancet 386 (9998), 1049-1056, 2015 | 183 | 2015 |
| Thymic selection generates a large T cell pool recognizing a self-peptide in humans A Zippelius, MJ Pittet, P Batard, N Rufer, M de Smedt, P Guillaume, ... The Journal of experimental medicine 195 (4), 485-494, 2002 | 175 | 2002 |
| A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, ... Nature medicine 24 (7), 994-1004, 2018 | 174 | 2018 |
| Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases MJ Pittet, A Zippelius, DE Speiser, M Assenmacher, P Guillaume, ... The Journal of Immunology 166 (12), 7634-7640, 2001 | 157 | 2001 |
| Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade P Müller, M Kreuzaler, T Khan, DS Thommen, K Martin, K Glatz, S Savic, ... Science translational medicine 7 (315), 315ra188-315ra188, 2015 | 156 | 2015 |
| Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ... Cancer immunology research 3 (12), 1344-1355, 2015 | 148 | 2015 |
| Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines K Pantel, A Dickmanns, A Zippelius, C Klein, J Shi, W Hoechtlen-Vollmar, ... JNCI: Journal of the National Cancer Institute 87 (15), 1162-1168, 1995 | 138 | 1995 |
| Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international … RA Stahel, O Riesterer, A Xyrafas, I Opitz, M Beyeler, A Ochsenbein, ... The lancet oncology 16 (16), 1651-1658, 2015 | 130 | 2015 |
| Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 CS Garris, SP Arlauckas, RH Kohler, MP Trefny, S Garren, C Piot, ... Immunity 49 (6), 1148-1161. e7, 2018 | 123 | 2018 |
| The immune system and cancer evasion strategies: therapeutic concepts S Muenst, H Läubli, SD Soysal, A Zippelius, A Tzankov, S Hoeller Journal of internal medicine 279 (6), 541-562, 2016 | 117 | 2016 |
| Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study VH Koelzer, SI Rothschild, D Zihler, A Wicki, B Willi, N Willi, M Voegeli, ... Journal for immunotherapy of cancer 4 (1), 1-8, 2016 | 110 | 2016 |
